[go: up one dir, main page]

NO20050933L - Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav - Google Patents

Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav

Info

Publication number
NO20050933L
NO20050933L NO20050933A NO20050933A NO20050933L NO 20050933 L NO20050933 L NO 20050933L NO 20050933 A NO20050933 A NO 20050933A NO 20050933 A NO20050933 A NO 20050933A NO 20050933 L NO20050933 L NO 20050933L
Authority
NO
Norway
Prior art keywords
pravastatin
formulations
methods
pharmaceutical formulations
pravastatin pharmaceutical
Prior art date
Application number
NO20050933A
Other languages
English (en)
Inventor
John G Devane
Jackie Butler
Paul Stark
Original Assignee
Biovail Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biovail Lab Inc filed Critical Biovail Lab Inc
Publication of NO20050933L publication Critical patent/NO20050933L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Det beskrives formuleringer som omfatter en terapeutisk effektiv mengde pravastatin, eller et farmasøytisk akseptabelt salt derav. Formuleringene er beregnet på å forhindre inaktivering av pravastatin i magesekken, begrense systemisk pravastatineksponering i kroppen og maksimalisere lever-spesifikk absorpsjon av medikamentet. Formuleringene er særlig anvendelige til behandling og/eller forhindring av tilstander som har fordel av reduserte nivåer av lipider og/eller kolesterol i kroppen.
NO20050933A 2002-09-03 2005-02-21 Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav NO20050933L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40726902P 2002-09-03 2002-09-03
PCT/IB2003/004523 WO2004021973A2 (en) 2002-09-03 2003-09-03 Pravastatin pharmaceutical formulations and methods of their use

Publications (1)

Publication Number Publication Date
NO20050933L true NO20050933L (no) 2005-04-18

Family

ID=31978448

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050933A NO20050933L (no) 2002-09-03 2005-02-21 Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav

Country Status (10)

Country Link
US (1) US20040132806A1 (no)
EP (2) EP1551356A2 (no)
JP (1) JP2006504686A (no)
AU (1) AU2003267756A1 (no)
CA (1) CA2497896A1 (no)
IL (1) IL166773A0 (no)
MX (1) MXPA05002095A (no)
NO (1) NO20050933L (no)
PL (1) PL375712A1 (no)
WO (1) WO2004021973A2 (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987322B2 (en) 2003-11-04 2015-03-24 Circ Pharma Research And Development Limited Pharmaceutical formulations for carrier-mediated transport statins and uses thereof
AU2015301596B2 (en) * 2014-08-13 2020-04-16 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
WO2016161085A1 (en) 2015-04-01 2016-10-06 Cedars-Sinai Medical Center Anti-methanogenic lovastatin analogs or derivatives and uses thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4200098A (en) 1978-10-23 1980-04-29 Alza Corporation Osmotic system with distribution zone for dispensing beneficial agent
US4557925A (en) 1982-07-08 1985-12-10 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4629620A (en) * 1984-09-05 1986-12-16 Ab Ferrosan Membrane-coated sustained-release tablets and method
US4904474A (en) * 1988-01-25 1990-02-27 Alza Corporation Delivery of drug to colon by oral disage form
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US4997658A (en) * 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
CA2045428A1 (en) * 1990-06-26 1991-12-27 Alfred W. Alberts Method for enhancing the lowering of plasma cholesterol levels
US5225202A (en) * 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5573776A (en) 1992-12-02 1996-11-12 Alza Corporation Oral osmotic device with hydrogel driving member
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
WO1997031546A1 (en) * 1996-02-29 1997-09-04 Nutri Pharma As Composition and its use as a food supplement or for lowering lipids in serum
US6056977A (en) * 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US5916595A (en) * 1997-12-12 1999-06-29 Andrx Pharmaceutials, Inc. HMG co-reductase inhibitor
UA69413C2 (uk) * 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
UA73092C2 (uk) * 1998-07-17 2005-06-15 Брістол-Майерс Сквібб Компані Таблетка з ентеросолюбільним покриттям і спосіб її приготування
WO2000033821A1 (en) * 1998-12-07 2000-06-15 Bristol-Myers Squibb Company Enteric coated pravastatin bead formulation
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US6569461B1 (en) * 1999-03-08 2003-05-27 Merck & Co., Inc. Dihydroxy open-acid and salts of HMG-CoA reductase inhibitors
US6592890B1 (en) * 1999-10-20 2003-07-15 Oxibio, Inc. Conveyance of anti-infective activity to wound dressings
AU5340101A (en) * 2000-04-11 2001-10-23 Atherogenics Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality

Also Published As

Publication number Publication date
MXPA05002095A (es) 2005-06-06
IL166773A0 (en) 2006-01-15
PL375712A1 (en) 2005-12-12
EP2033631A3 (en) 2009-06-03
WO2004021973A2 (en) 2004-03-18
EP1551356A2 (en) 2005-07-13
EP2033631A2 (en) 2009-03-11
WO2004021973A3 (en) 2004-05-21
AU2003267756A1 (en) 2004-03-29
US20040132806A1 (en) 2004-07-08
CA2497896A1 (en) 2004-03-18
JP2006504686A (ja) 2006-02-09

Similar Documents

Publication Publication Date Title
NO20061325L (no) Kombinasjon av legemidler for behandling av neoplasmer
CY1106107T1 (el) Φαρμακολογικες μορφοποιησεις που πepιλαμβανουν ρεσβepατρολη και χρηση αυτων
WO2005094374A3 (en) Hydrazide-containing cftr inhibitor compounds and uses thereof
EA200901492A1 (ru) Лечение доброкачественной гиперплазии простаты селективным модулятором рецептора андрогенов (sarm)
EP2444072A3 (en) Non-mucoadhesive film dosage forms
MX9200992A (es) Composicion farmaceutica que tiene como ingrediente activo 3-[2-(dimetilamino)etil]-n-metil-1h-indol-5-metanosulfonamida y procedimiento para su preparacion.
PT1083879E (pt) Metodos e dispositivos para proporcionar uma terapia de drogas prolongada
DE60315479D1 (de) Pyrimidinamid derivate und deren verwendung
MXPA05003366A (es) Inhibidores de la proteina reguladora de conductancia transmembranal de la fibrosis quistica y usos de los mismos.
NO20050060L (no) Medikament for behandling av overaktiv blaere
SV2002000036A (es) Inhibidores de acido abierto y sales de dihidroxilo de reductasa hmg-co-a ref.b.11111/rm/ma
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2024009444A (es) Métodos de tratamiento para la fibrosis quística
NO20101070L (no) Fremgangsmate til dosering av et medikament, samt doseringsform
NO20062432L (no) Farmasoytiske formuleringer for baeremedierte transportstatiner og anvendelse derav
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
JP2005511619A5 (no)
WO2004041191A3 (en) Methods for the treatment, prevention and management of macular degeneration
NO20050933L (no) Pravastatin farmasoytiske formuleringer og fremgangsmater for anvendelse derav
WO2005039497A3 (en) Methods and compositions comprising thalidomide for treatment of fibromyalgia
TW200638927A (en) Bambuterol and integrin inhibitor combination
WO2005046594A3 (en) Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application